全文获取类型
收费全文 | 11066篇 |
免费 | 682篇 |
国内免费 | 84篇 |
专业分类
耳鼻咽喉 | 85篇 |
儿科学 | 151篇 |
妇产科学 | 151篇 |
基础医学 | 1334篇 |
口腔科学 | 209篇 |
临床医学 | 1081篇 |
内科学 | 3102篇 |
皮肤病学 | 131篇 |
神经病学 | 906篇 |
特种医学 | 369篇 |
外科学 | 1841篇 |
综合类 | 58篇 |
一般理论 | 1篇 |
预防医学 | 763篇 |
眼科学 | 85篇 |
药学 | 694篇 |
中国医学 | 17篇 |
肿瘤学 | 854篇 |
出版年
2024年 | 10篇 |
2023年 | 84篇 |
2022年 | 155篇 |
2021年 | 374篇 |
2020年 | 192篇 |
2019年 | 364篇 |
2018年 | 468篇 |
2017年 | 292篇 |
2016年 | 286篇 |
2015年 | 363篇 |
2014年 | 500篇 |
2013年 | 607篇 |
2012年 | 962篇 |
2011年 | 978篇 |
2010年 | 539篇 |
2009年 | 437篇 |
2008年 | 707篇 |
2007年 | 741篇 |
2006年 | 624篇 |
2005年 | 680篇 |
2004年 | 621篇 |
2003年 | 544篇 |
2002年 | 550篇 |
2001年 | 100篇 |
2000年 | 70篇 |
1999年 | 90篇 |
1998年 | 97篇 |
1997年 | 54篇 |
1996年 | 52篇 |
1995年 | 45篇 |
1994年 | 33篇 |
1993年 | 36篇 |
1992年 | 30篇 |
1991年 | 26篇 |
1990年 | 11篇 |
1989年 | 16篇 |
1988年 | 10篇 |
1987年 | 6篇 |
1986年 | 17篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1982年 | 3篇 |
1981年 | 5篇 |
1979年 | 4篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1973年 | 3篇 |
1971年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
曾正陪 《中华医学信息导报》2006,21(17):7-7
由中华医学会内分泌学分会主办,国际内分泌学会参加的2006年内分泌代谢性疾病系列研讨会——全脚内分泌肿瘤基础和临床研究专题研讨会,于7月7~9日在西南省昆明市举办。此次大会是中华医学会内分泌学分会与国际内分泌学会首次联合举办的大会。国际内分泌学会山执行委员,负责学术会议的主席、肾上腺疾病研究方面的专家法国Xavier Bertagna教授带队,由国际内分泌学会邀请了分别在神经内分泌和甲状腺疾病领域深有研究的著名专家英旧Ashley Grossman教授和美国James A Fagha教授,…… 相似文献
92.
Frédéric Barbey Noureddine Brakch Ale Linhart Xavier Jeanrenaud Thomas Palecek Jan Bultas Michel Burnier & Daniel Hayoz 《Acta paediatrica (Oslo, Norway : 1992)》2006,95(S451):63-68
Aim: Fabry disease is considered primarily as a progressive small vessel disease, with ischaemic degenerative lesions involving the kidneys, brain and heart. Macrovascular involvement in male patients includes an accelerated wall hypertrophy of the radial artery and a thickening of the intima–media of the common carotid artery. The aim of this study is to evaluate the prevalence and severity of carotid artery atherosclerosis in hemizygous and heterozygous patients with Fabry disease, compared with a matched control population.
Methods: The common carotid artery intima–media thickness (IMT) of 53 patients with Fabry disease (24 men, 29 women) was measured by high-definition ultrasonography, and the presence or absence of atherosclerotic plaques reported. Results were compared with those of 120 age-matched healthy individuals (83 men, 37 women).
Results: The common carotid artery IMT was increased to the same extent in male and female patients with Fabry disease (706±211 µm and 749±395 µm, respectively) compared with that of the control population (614±113 µm). In the Fabry population, IMT did not correlate with either systolic blood pressure or with renal function (plasma creatinine). In the control population, only systolic blood pressure was positively and significantly correlated with IMT. Atherosclerotic plaques in the common carotid artery were not observed in any patient with Fabry disease, whereas 34% of the control population had carotid artery plaques, as evidenced by focal non-homogeneous intima–media thickening greater than 1.2 mm.
Conclusion: This study presents evidence of a major increase in common carotid artery IMT, both in hemizygous and heterozygous patients with Fabry disease, in the absence of focal atherosclerotic plaques. These results suggest that the conduit arteries may be protected from atherosclerosis in Fabry disease. 相似文献
Methods: The common carotid artery intima–media thickness (IMT) of 53 patients with Fabry disease (24 men, 29 women) was measured by high-definition ultrasonography, and the presence or absence of atherosclerotic plaques reported. Results were compared with those of 120 age-matched healthy individuals (83 men, 37 women).
Results: The common carotid artery IMT was increased to the same extent in male and female patients with Fabry disease (706±211 µm and 749±395 µm, respectively) compared with that of the control population (614±113 µm). In the Fabry population, IMT did not correlate with either systolic blood pressure or with renal function (plasma creatinine). In the control population, only systolic blood pressure was positively and significantly correlated with IMT. Atherosclerotic plaques in the common carotid artery were not observed in any patient with Fabry disease, whereas 34% of the control population had carotid artery plaques, as evidenced by focal non-homogeneous intima–media thickening greater than 1.2 mm.
Conclusion: This study presents evidence of a major increase in common carotid artery IMT, both in hemizygous and heterozygous patients with Fabry disease, in the absence of focal atherosclerotic plaques. These results suggest that the conduit arteries may be protected from atherosclerosis in Fabry disease. 相似文献
93.
Magliano L Fadden G Economou M Held T Xavier M Guarneri M Malangone C Marasco C Maj M 《Social psychiatry and psychiatric epidemiology》2000,35(3):109-115
Background: To date, only few data are available on how family burden in schizophrenia changes over time. In addition, no study has
explored how such factors as coping styles and social support influence burden over time. This paper presents the 1-year follow-up
data from the BIOMED I study on family burden and coping strategies in schizophrenia. Methods: A sample of 159 relatives of patients with schizophrenia living in five European countries was followed up prospectively
for 1 year with regard to burden and coping strategies, using validated questionnaires. Results: In the sample as a whole, the burden was stable. A reduction of family burden over time was found among relatives who adopted
less emotion-focused coping strategies and received more practical support from their social network. In addition, family
burden decreased in relation to the improvement of patient's social functioning. Conclusions: When relatives of patients with schizophrenia are able to improve their coping strategies, it is possible for burden to
be reduced even after several years. This points to the necessity to provide families of chronic psychotic patients with psychoeducational
interventions emphasising the adoption of an effective coping style.
Accepted: 22 November 1999 相似文献
94.
Maria Carmen Iglesias-Osma Sandy Bour Maria Jose Garcia-Barrado Virgile Visentin Maria Francisca Pastor Xavier Testar Luc Marti Gemma Enrique-Tarancon Philippe Valet Julio Moratinos Christian Carpn 《Pharmacological research》2005,52(6):21-484
It has been reported that benzylamine reduces blood glucose in rabbits, stimulates hexose uptake, and inhibits lipolysis in mouse, rabbit, and human adipocytes. In the presence of vanadate, benzylamine is also able to improve glucose disposal in normoglycaemic and diabetic rats. Such insulin-mimicking properties are the consequence of hydrogen peroxide production during benzylamine oxidation by semicarbazide-sensitive amine oxidase (SSAO). The aim of the study was to determine whether other SSAO-substrates could share such potential antidiabetic properties. Thus, mafenide, a synthetic antimicrobial sulfonamide structurally related to benzylamine, and which has been recently reported to interact with SSAO, was tested in the above mentioned models, in parallel with methylamine, a proposed endogenous SSAO-substrate. All tested amines stimulated glucose uptake and inhibited lipolysis in rat and mouse fat cells. Methylamine and benzylamine, but not mafenide, reduced the hyperglycaemic response during a glucose tolerance test in rabbits while the three amines tested were devoid of insulin-releasing activity under both in vivo and in vitro conditions. In human adipocytes, mafenide did not stimulate glucose transport since it was not a high-affinity substrate for SSAO and generated less hydrogen peroxide than benzylamine or methylamine. Therefore, mafenide could not be considered as an antidiabetic drug despite being oxidized and exhibiting insulin-mimicking effects in rat and mouse adipocytes. By contrast, the endogenous substrate methylamine improved glucose utilization in all in vitro and in vivo models, leading to consider novel SSAO substrates as drugs with potential anti-hyperglycaemic properties. 相似文献
95.
96.
Xavier Leleu Ga?lle Le Friec Thierry Facon Laurence Amiot Renée Fauchet Bernadette Hennache Valérie Coiteux Ibrahim Yakoub-Agha Sylvain Dubucquoi Hervé Avet-Loiseau Claire Mathiot Régis Bataille Jean-Yves Mary 《Clinical cancer research》2005,11(20):7297-7303
Serum beta2-microglobulin, the light chain of the HLA class I molecular complex, remains one of the best survival prognostic factors in multiple myeloma, but other HLA class I molecules might be of interest in monoclonal gammopathies. In this study, we evaluate total soluble HLA class I (HLA-Is) and soluble HLA-G (HLA-Gs) in 103 patients with newly diagnosed multiple myeloma, 30 patients with monoclonal gammopathy of undetermined significance (MGUS), and 30 healthy subjects, studying their prognostic value in multiple myeloma. In multiple myeloma patients, HLA-Is and HLA-Gs median values were 0.8 microg/mL and 28 ng/mL, respectively. Median HLA-Is concentration was higher in stage II and III multiple myeloma patients than in stage I multiple myeloma, MGUS, and control patients. Median HLA-Gs was significantly lower in healthy controls than in MGUS and multiple myeloma patients. A high level of HLA-Is (> or =2.1 microg/mL) was predictive of short survival (P = 0.017). For each given level of beta2-microglobulin, the relative risk of death was higher for patients with HLA-Is > or = 2.1 microg/mL than in patients with a lower level (P = 0.047). HLA-Gs, a marker of monoclonal gammopathy, was of no prognostic value, but the addition of HLA-Is to beta2-microglobulin produced an efficient prognostic score (P < 0.0001). HLA-Is is a new marker of multiple myeloma tumor load and provides additional survival prognostic information to beta2-microglobulin. 相似文献
97.
Carolina de Mattos Duarte Hugo Verli Joo Xavier de Araújo-Júnior Isac Almeida de Medeiros Eliezer J. Barreiro Carlos Alberto Manssour Fraga 《European journal of pharmaceutical sciences》2004,23(4-5):363-369
We describe herein the structural optimization of new piperamide analogues, designed from two natural prototypes, piperine 1 and piperdardine 2, obtained from Piper tuberculatum Jacq. (Piperaceae). Molecular modeling studies using semiempirical AM1 method were made in order to establish rational modifications to optimize them by molecular simplification. The targeted compounds (10) and (11) were respectively obtained using benzaldehyde (12) and para-anisaldehyde (13) as starting materials. 1H NMR spectra showed that the target compounds were diastereoselectively obtained as the (E)-isomer, the same geometry of the natural prototypes. These new synthetic amides presented significant hypotensive effects in cardiovascular essays using in vivo methodologies. Compound 11 (N-[5-(4′-methoxyphenyl)-2(E)-pentenoyl]thiomorpholine) showed a potency 10,000 times greater than its prototype 5, evidencing an optimization of the molecular architecture for this class of hypotensive drug candidates. 相似文献
98.
Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention 总被引:2,自引:0,他引:2
Juan F. Ascaso Arturo Fernández-Cruz Pedro González Santos Antonio Hernández Mijares Alipio Mangas Rojas Prof. Jesus Millán Luis Felipe Pallardo Juan Pedro-Botet Francisco Pérez-Jiménez Gonzalo Pía Xavier Pintó Ignacio Plaza Juan Rubiés-Prat 《Am J Cardiovasc Drugs》2004,4(5):299-314
In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (<100 mg/dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (>20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome. 相似文献
99.
Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma
下载免费PDF全文
![点击此处可从《International journal of cancer. Journal international du cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Pablo García‐Sanz Juan Carlos Triviño Eva Colás Alejandro Rojo‐Sebastián Ángel García Sonia Gatius María Ruiz Jaime Prat Rafael López‐López Miguel Abal Antonio Gil‐Moreno Jaume Reventós Xavier Matias‐Guiu Gema Moreno‐Bueno 《International journal of cancer. Journal international du cancer》2017,140(7):1551-1563
In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non‐endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome. We focused on low‐grade, non‐ultramutated tumours as these tumours have a worse prognosis than the ultramutated POLE‐positive endometrioid endometrial carcinomas (EECs). We performed exome‐sequencing of 11 EECs with matched normal tissue and subsequently validated 15 candidate genes in 76 samples. For the first time, we show that mutations in chromatin remodelling‐related genes (KMT2D, KMT2C, SETD1B and BCOR) and in DNA‐repair‐related genes (BRCA1, BRCA2, RAD50 and CHD4) are frequent in this subtype of endometrial cancer. The alterations to these genes occurred with frequencies ranging from 35.5% for KMT2D to 10.5% for BRCA1 and BCOR, with some showing a tendency toward co‐occurrence (RAD50‐KMT2D and RAD50‐SETD1B). All these genes harboured specific mutational hotspots. In addition, the mutational status of KMT2C, KMT2D and SETD1B helps to predict the degree of myometrial invasion, a critical prognostic feature. These results highlight the possible implication of these genes in this disease, creating opportunities for new therapeutic approaches. 相似文献
100.
Xavier Paoletti Birgit Geoerger François Doz André Baruchel François Lokiec Christophe Le Tourneau 《European journal of cancer (Oxford, England : 1990)》2013,49(10):2392-2402
BackgroundDose-finding phase I trials in children are usually carried out once clinical data have already been accumulated in the adult population. The objectives, place and role of paediatric dose-finding trials are investigated in the era of molecularly targeted agents (MTAs).MethodsPhase I paediatric oncology trials of MTAs approved in adults before June 15th, 2012 were reviewed. The recommended phase II dose (RPIID) was compared to the body surface area (BSA)-adjusted approved dose in adults. Toxicity profile was compared to the findings from the corresponding adult phase I trials.ResultsFifteen MTAs out of a total of 25 MTAs approved in the adult population have been evaluated in 19 single-agent phase I paediatric trials. Trials included a median of 30 children with a median of four dose levels. The paediatric RPIID ranged between 90% and 130% of the BSA-adjusted approved dose in adults for 70% of the trials (75% of compounds). Overall, 63% of children did not receive an optimal dose. The most marked discrepancy involved sunitinib. Safety profiles described in phase I paediatric trials were usually similar to those reported in the adult population.ConclusionsThese data suggest that dose-finding studies might not be necessary for all the MTAs in children. Except in the case of a narrow therapeutic index, early-phase trials validating pharmacokinetics, pharmacodynamic markers and efficacy findings from adults while controlling for toxicity appear to be a possible alternative to accelerate drug development in paediatric oncology. 相似文献